Tuesday, March 10, 2009

Merck and Schering-Plough – sign o’ the times...

Monday morning heralded the merger/buy out of Merck over Schering-Plough.

The various news articles are stating that Merck needed to refresh it’s portfolio and pipeline and Schering has quite a bit to offer as well as many products on long term patent protection. There is quite a bit of synergy between the two and of course they have been “test” dating on a few cholesterol products lately....

Industry insiders say that we should keep our eyes on Bristol Myers Squibb, Eli Lilly and Sanofi Aventis (ranked number one in Europe and third largest in the world by some industry standards) as they seem to all be on the hunt for acquisitions.

Monday’s business deal now makes Merck the number 2 Pharmaceutical company. Stay tuned for an updated list of rankings...

There will be significant job losses and some numbers being bandied about are about 16,000 jobs.

These are tough times.

The question is which jobs will go, which jobs are seen as redundant?

Share your thoughts and opinions.

1 comment:

  1. “About 60 percent of the cuts will come from marketing and administration, and the rest from manufacturing and research and development” AP, 3/9/09.

    In the current “merger mania” situation, the big fish are gobbling up all the smaller fish and the little tiny fish are toast, which will result in a couple of choices “for the folks,” i.e., Wal-Mart or Costco. The big difference will be price. Merck will have a “patent free” edge on biologics, the new medicine that will cost more than what consumers are paying now.


Note - Due to a time out issue with Blogger, you may receive a message that requires you to resend your comment. This will not affect its contents.